Annovis Bio Aktie

Annovis Bio für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2PNH2 / ISIN: US03615A1088

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
13.08.2025 05:10:10

Annovis Bio Narrows Loss in Q2

Annovis Bio (NYSE:ANVS), a biotechnology company focused on innovative treatments for neurodegenerative diseases, released its earnings results for the second quarter on August 12, 2025. The company reported a net loss per share of $(0.32) (GAAP), which was $0.08 better than analyst expectations of $(0.40) (GAAP). No revenue was reported, matching estimates, as Annovis remains in a pre-commercial stage. The quarter featured ongoing cost discipline, an improved cash position as of June 30, 2025 compared to December 31, 2024, and continuing clinical progress with its lead drug candidate, buntanetap. Overall, the period revealed steady operational management during a critical stage for the business. Source: Analyst estimates for the quarter provided by FactSet. Annovis Bio develops therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s primary asset, buntanetap, aims to block the production of several toxic brain proteins involved in these diseases. This multi-target approach is designed to address the complex biological processes behind AD and PD, going beyond the single-protein focus of many competing drugs.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Nachrichten zu Annovis Bio Inc Registered Shs Accred Invmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Annovis Bio Inc Registered Shs Accred Invmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Annovis Bio Inc Registered Shs Accred Inv 1,73 0,82% Annovis Bio Inc Registered Shs Accred Inv
Q2 Holdings Inc 60,50 -2,42% Q2 Holdings Inc